Ankle Fusion or Total Replacement?
In a large study of British patients needing surgical treatment for advanced arthritis in the ankle, fusion appeared to be a better option than total ankle replacement.
Read Article
I ALWAYS recommend paraffin wax baths for stiffness, RA, OA, PSS, etc.
Here are some instructions for home use https://t.co/CTI4K2kHf9 https://t.co/i0kO99vdYc
Dr. John Cush @RheumNow( View Tweet )
Ankle Fusion or Total Replacement?
In a large study of British patients needing surgical treatment for advanced arthritis in the ankle, fusion appeared to be a better option than total ankle replacement.
https://t.co/ZFbd2VinpP https://t.co/QCqMkxNLoQ
Dr. John Cush @RheumNow( View Tweet )
B Cell Depleters (2.21.2025)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.
https://t.co/PRjy4a1BG9 https://t.co/3J4NSmn6Su
Dr. John Cush @RheumNow( View Tweet )
Deucravacitinib in Psoriasis - 5 Year Outcomes
BMS released new five-year results from the POETYK PSO long-term extension (LTE) trial of deucravacitinib in treating patients with moderate-to-severe plaque psoriasis. The data was presented by Dr. Marc Lebwohl at the Winter… https://t.co/as7QR8RTyx https://t.co/yNluBPR7fO
Dr. John Cush @RheumNow( View Tweet )
Deucravacitinib in Psoriasis - 5 Year Outcomes
BMS released new five-year results from the POETYK PSO long-term extension (LTE) trial of deucravacitinib in treating patients with moderate-to-severe plaque psoriasis. The data was presented by Dr. Marc Lebwohl at the Winter Clinical Dermatology Conference in Hawaii
Combination biologics in PsA: are we there yet?
Combination therapy is well-established in rheumatoid arthritis, but its efficacy in psoriatic arthritis (PsA) remains uncertain. Despite effective treatment options, there is a need for solutions for patients unresponsive to… https://t.co/uqLnxLIktM https://t.co/awwaVPOZTu
Dr. John Cush @RheumNow( View Tweet )
The Cartel is Coming for Rheumatology
"What Do Blockbuster Drugs & The Black Market All Have in Common?" asked Dr. Madelaine Feldman at RheumNow Live 2025. They thrive, she explained, on market exclusivity "... until they don't." At first glance, the pharmaceutical marketplace may not appear like a crime drug ring, but Dr.
Read Article
Combination biologics in PsA: are we there yet?
Despite various and efficacious options for management of PsA there is still an unmet need for patients with inadequate responses to current therapies or difficult-to-treat disease. The role of dual biologic therapy targeting different inflammatory pathways has become an area of great interest
Read Article
“Preventing” Arthritis in Psoriasis
Prevention of the development of our systemic rheumatic diseases in individuals deemed at risk, or with some form of precursor disease process, has been a hot topic in recent years.
https://t.co/nGKGUkKVUl https://t.co/PruJZLAq9n
Dr. John Cush @RheumNow( View Tweet )
“Preventing” Arthritis in Psoriasis
The always compelling Dr. Alexis Ogdie explored whether aggressive treatment of psoriasis can prevent psoriatic arthritis in an excellent Saturday morning session at RheumNow Live 2025.
Read Article
Study of 702 pts who transitioned from PsO to PsA (median 9yrs) - no baseline differences in PsA pts who transitioned late (>9yrs); but on follow-up, the late group had lower Dz activity, less csDMARD use, but no difference in radiographic progression https://t.co/vwgfa5z6BE https://t.co/N1yUcrcR2o
Links:
Dr. John Cush @RheumNow( View Tweet )
New for HS
- Bimekizumab is 3rd FDA approved therapy based on BE HEARD 1&2
- Other approved ADA (2015, PIONEER 1&2), SEC (2023, SUNRISE/SUNSHINE)
Clinical trials:
IL23 failed, ILalpha failed
Brodulamab (IL17a) clinically meaningful response
TNF trials
@RheumNow #ACR2025 https://t.co/BfzwNQ1wUB
Links:
Eric Dein @ericdeinmd( View Tweet )
1/3 of #axial #PsA
👇
No #SI joint changes , only #axial
@RheumNow #RNL2025
Catherine Blackwell
#ClinicalPearl https://t.co/YmoipL1bME
Janet Pope @Janetbirdope( View Tweet )
P2 Trial: DEU in PsA
Encouraging results for DCV 6 and 12 mg qd.
ACR20 63% for DCV 12 mg (p=0.0004)
Not yet FDA approved for PsA, only PsO
Pending P3
P2: DEU in SLE - PAISLEY
Improved SRI(4), CLASI-50 at w32
Merola
#RNL2025 @RheumNow https://t.co/RV7OPaZWjx
Links:
Eric Dein @ericdeinmd( View Tweet )
Combination therapy in PsA . Regulatory and reimbursement issues may inhibit such strategies (and potential adverse event concerns) but anecdotal evidence would suggest a role in difficult to treat cases. @RheumNow #RNL2025 https://t.co/IIoUiJyP95
Richard Conway @RichardPAConway( View Tweet )
#HOT #topic
Will #Rx of #PsO PREVENT onset of #PsA
Well, maybe 🤔
Alexis R Ogdie @RheumNow #RNL2025
70% of #psoriatic #arthritis is preceded by #psoriasis
Still a bit of a debate re prevention of PsA https://t.co/7bce8kcjdr
Janet Pope @Janetbirdope( View Tweet )
Risk factors for development of PsA in psoriasis. Psoriasis severity, obesity, and depression. @alexisogdie @RheumNow @RNL2025 https://t.co/obMDBvLLnx
Richard Conway @RichardPAConway( View Tweet )
Great graph from @AlexisOgdie on the effect of biologic treatment on PsA development in psoriasis. Obvious front-loading in those who need systemic therapy. But over time those who don't appear to develop more PsA @RheumNow @RNL2025 https://t.co/UxUZyKb0NA
Richard Conway @RichardPAConway( View Tweet )
Can treatment of PsO prevent PsA?
-Severity of PsO and obesity->Risk fx for PsA
-PRESTO scores: Predicts whether you will develop PsA in the next year vs next 5 years
-Does ttx of PsO impact development of PsA?
Trials are mostly observational (several confounders)
TriNetX data:… https://t.co/TBv3Y2TLZv https://t.co/1K0MtMQ5gn
Links:
Adela Castro @AdelaCastro222( View Tweet )
Predicting #PsA
PRESTO study #obvious risks are #predictive
Alexis R Ogdie @RheumNow #RNL2025
bad PsO 2X ^PsA
High BMI
Depression
Modifiable risks #psoriasis #psoriatic #arthritis https://t.co/pOxidCWcg5
Janet Pope @Janetbirdope( View Tweet )
QD Clinic - New Palmoplantar Psoriasis and PsA
New Onset Palmoplantar PsO and PsA - what are the options?
Features Dr. Jack Cush.
QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025
Register at https://t.co/2dcFVgu8z6… https://t.co/3ubBL6HVGF https://t.co/Zdd6Dih5eZ
Links:
Dr. John Cush @RheumNow( View Tweet )
Drug Naming Games (2.7.2025)
Dr. Jack Cush reviews the news, regulatory and journal reports from the past week on RheumNow.com.
Read Article
Granzyme - a major driver of inflammatory & autoimmune diseases
EurekAlert!
Our immune system is armed with an array of defenses designed to detect and eliminate harmful threats. One of its most powerful defense mechanisms is the complement system—a group of proteins that patrols our body, ever vigilant for signs of infection or injury. Now, over 100 years after the
Read Article
Is IL-23i better than IL-17i at lowering PsA risk? Retrospective, real-world EHR data study from TriNetX shows that among 4580 adult psoriasis pts (2,273 on IL23i vs 2,307 on IL17i), IL23i had signif lower PsA incidence (HR 0.60; 0.44–0.82, P 0.001), esp if 41-65 yrs (HR 0.42) &… https://t.co/ZuCAiOTIke https://t.co/8PkDCugYy0
Dr. John Cush @RheumNow( View Tweet )
Recent Blogs
